Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,1-dichloroethene | decreases expression | ISO | Fbln7 (Mus musculus) | 6480464 | vinylidene chloride results in decreased expression of FBLN7 mRNA | CTD | PMID:26682919 | 1,2-dichloroethane | decreases expression | ISO | Fbln7 (Mus musculus) | 6480464 | ethylene dichloride results in decreased expression of FBLN7 mRNA | CTD | PMID:28960355 | 1,2-dimethylhydrazine | increases expression | ISO | Fbln7 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in increased expression of FBLN7 mRNA | CTD | PMID:22206623 | 17beta-estradiol | multiple interactions | ISO | FBLN7 (Homo sapiens) | 6480464 | [Estradiol co-treated with TGFB1 protein] results in increased expression of FBLN7 mRNA | CTD | PMID:30165855 | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | Fbln7 (Mus musculus) | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased expression of FBLN7 mRNA | CTD | PMID:20188158 | 4,4'-sulfonyldiphenol | increases expression | ISO | Fbln7 (Mus musculus) | 6480464 | bisphenol S results in increased expression of FBLN7 mRNA | CTD | PMID:30951980 | 4-hydroxyphenyl retinamide | increases expression | ISO | Fbln7 (Mus musculus) | 6480464 | Fenretinide results in increased expression of FBLN7 mRNA | CTD | PMID:28973697 | acrylamide | decreases expression | EXP | | 6480464 | Acrylamide results in decreased expression of FBLN7 mRNA | CTD | PMID:28959563 | aflatoxin B1 | affects expression | ISO | FBLN7 (Homo sapiens) | 6480464 | Aflatoxin B1 affects the expression of FBLN7 protein | CTD | PMID:20106945 | aflatoxin B1 | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased expression of FBLN7 mRNA | CTD | PMID:22100608 and PMID:27153756 | Aflatoxin B2 alpha | increases methylation | ISO | FBLN7 (Homo sapiens) | 6480464 | aflatoxin B2 results in increased methylation of FBLN7 intron | CTD | PMID:30157460 | arsenite(3-) | increases expression | ISO | Fbln7 (Mus musculus) | 6480464 | arsenite results in increased expression of FBLN7 mRNA | CTD | PMID:18929588 | arsenite(3-) | multiple interactions | ISO | Fbln7 (Mus musculus) | 6480464 | TRP53 protein affects the reaction [arsenite results in increased expression of FBLN7 mRNA] | CTD | PMID:18929588 | belinostat | multiple interactions | ISO | FBLN7 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA | CTD | PMID:27188386 | belinostat | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | belinostat results in decreased expression of FBLN7 mRNA | CTD | PMID:26272509 | benzo[a]pyrene | affects methylation | ISO | FBLN7 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of FBLN7 3' UTR and Benzo(a)pyrene affects the methylation of FBLN7 promoter | CTD | PMID:27901495 | benzo[a]pyrene | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of FBLN7 mRNA | CTD | PMID:32234424 | benzo[a]pyrene | increases methylation | ISO | FBLN7 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of FBLN7 5' UTR | CTD | PMID:27901495 | benzo[e]pyrene | affects methylation | ISO | FBLN7 (Homo sapiens) | 6480464 | benzo(e)pyrene affects the methylation of FBLN7 intron | CTD | PMID:30157460 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of FBLN7 mRNA | CTD | PMID:25181051 and PMID:30816183 | bisphenol A | decreases methylation | ISO | FBLN7 (Homo sapiens) | 6480464 | bisphenol A results in decreased methylation of FBLN7 gene | CTD | PMID:31601247 | bisphenol A | increases expression | ISO | Fbln7 (Mus musculus) | 6480464 | bisphenol A results in increased expression of FBLN7 mRNA | CTD | PMID:30951980 | bisphenol F | increases expression | ISO | Fbln7 (Mus musculus) | 6480464 | bisphenol F results in increased expression of FBLN7 mRNA | CTD | PMID:30951980 | cadmium atom | multiple interactions | ISO | Fbln7 (Mus musculus) | 6480464 | [Tetradecanoylphorbol Acetate co-treated with [Cadmium Chloride results in increased abundance of Cadmium]] affects the expression of FBLN7 mRNA | CTD | PMID:31904401 | cadmium dichloride | multiple interactions | ISO | Fbln7 (Mus musculus) | 6480464 | [Tetradecanoylphorbol Acetate co-treated with [Cadmium Chloride results in increased abundance of Cadmium]] affects the expression of FBLN7 mRNA | CTD | PMID:31904401 | cyclosporin A | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | Cyclosporine results in decreased expression of FBLN7 mRNA | CTD | PMID:20106945 | diquat | decreases expression | ISO | Fbln7 (Mus musculus) | 6480464 | Diquat results in decreased expression of FBLN7 mRNA | CTD | PMID:36851058 | dorsomorphin | multiple interactions | ISO | FBLN7 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | entinostat | multiple interactions | ISO | FBLN7 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA | CTD | PMID:27188386 | entinostat | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | entinostat results in decreased expression of FBLN7 mRNA | CTD | PMID:26272509 | fulvestrant | increases methylation | ISO | FBLN7 (Homo sapiens) | 6480464 | Fulvestrant results in increased methylation of FBLN7 gene | CTD | PMID:31601247 | methapyrilene | affects methylation | ISO | FBLN7 (Homo sapiens) | 6480464 | Methapyrilene affects the methylation of FBLN7 intron | CTD | PMID:30157460 | N-Nitrosopyrrolidine | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | N-Nitrosopyrrolidine results in decreased expression of FBLN7 mRNA | CTD | PMID:32234424 | panobinostat | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | panobinostat results in decreased expression of FBLN7 mRNA | CTD | PMID:26272509 | panobinostat | multiple interactions | ISO | FBLN7 (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA | CTD | PMID:27188386 | paracetamol | affects expression | ISO | Fbln7 (Mus musculus) | 6480464 | Acetaminophen affects the expression of FBLN7 mRNA | CTD | PMID:17562736 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of FBLN7 mRNA | CTD | PMID:33387578 | paracetamol | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | Acetaminophen results in decreased expression of FBLN7 mRNA | CTD | PMID:29067470 | phenylmercury acetate | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of FBLN7 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | FBLN7 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA | CTD | PMID:27188386 | phorbol 13-acetate 12-myristate | multiple interactions | ISO | Fbln7 (Mus musculus) | 6480464 | [Tetradecanoylphorbol Acetate co-treated with [Cadmium Chloride results in increased abundance of Cadmium]] affects the expression of FBLN7 mRNA | CTD | PMID:31904401 | pioglitazone | multiple interactions | ISO | Fbln7 (Mus musculus) | 6480464 | [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FBLN7 mRNA | CTD | PMID:27935865 | rotenone | increases expression | ISO | Fbln7 (Mus musculus) | 6480464 | Rotenone results in increased expression of FBLN7 mRNA | CTD | PMID:32937126 | SB 431542 | multiple interactions | ISO | FBLN7 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | sodium arsenite | increases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | sodium arsenite results in increased expression of FBLN7 mRNA | CTD | PMID:29301061 | sodium arsenite | increases expression | ISO | Fbln7 (Mus musculus) | 6480464 | sodium arsenite results in increased expression of FBLN7 mRNA | CTD | PMID:37682722 | trichostatin A | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of FBLN7 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | FBLN7 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA | CTD | PMID:27188386 | valproic acid | affects expression | ISO | FBLN7 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of FBLN7 mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | FBLN7 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of FBLN7 mRNA | CTD | PMID:28001369 | vorinostat | multiple interactions | ISO | FBLN7 (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA | CTD | PMID:27188386 | XL147 | multiple interactions | ISO | Fbln7 (Mus musculus) | 6480464 | [N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of FBLN7 mRNA | CTD | PMID:27935865 | |